Recent regulatory decisions and clinical trials are transforming how doctors identify Alzheimer’s disease, with blood tests emerging as faster and less invasive alternatives to traditional spinal taps and brain scans. The U.S. Food and Drug Administration has approved four plasma tests to evaluate patients showing cognitive symptoms, while new international research demonstrates high accuracy across diverse healthcare settings, Yahoo News Singapore and Bioengineer.org reported.
The newly available blood tests measure specific biomarkers, primarily forms of phosphorylated tau and amyloid-beta proteins that accumulate in the brain as Alzheimer’s progresses. According to Yahoo News Singapore, the FDA-approved tests include Fujirebio Diagnostics’ Lumipulse G p-tau217/β-Amyloid 1-42 ratio test and Roche’s Elecsys p-Tau181, which was cleared as the first standalone triage tool for primary care environments. The FDA has also approved C2N Diagnostics’ PrecivityAD2 test for adults as young as 40 and Roche’s Elecsys p-Tau217 test for adults aged 55 and older showing cognitive symptoms.
Study validates test performance in community settings
Beyond regulatory approvals, real-world clinical performance was recently validated in a prospective multicenter study in Spain. As reported by Bioengineer.org, researchers evaluated 185 patients across seven memory clinics in Catalonia between June 2023 and February 2024. The trial compared automated plasma p-tau217 testing against traditional cerebrospinal fluid assays obtained via lumbar punctures.
The investigation, conducted by Hospital Clínic de Barcelona alongside six regional community centers including Hospital Universitari Santa Maria de Lleida and Hospital de Figueres, found that blood testing accurately detected cerebral amyloid pathology with an overall area under the curve of 0.916. Diagnostic accuracy remained highly consistent between the tertiary academic center at 91.6 percent and the six peripheral community hospitals at 91.9 percent, Bioengineer.org reported.
Researchers noted that using a dual-threshold model achieved 93.4 percent diagnostic accuracy among conclusive results. This approach successfully spared 74.1 percent of study participants from needing invasive spinal fluid tests or expensive positron emission tomography scans.
Coverage challenges and clinical guidelines
Despite these technological advances, medical experts stress that blood tests are currently intended only for patients who already exhibit symptoms of cognitive decline. Dr. Danita Jones, a neurologist at Cleveland Clinic in Weston, Florida, told Yahoo News Singapore that these biomarkers can sometimes appear in cognitively healthy individuals as part of normal aging without predicting future decline. Consequently, experts do not recommend screening asymptomatic individuals, even those with a family history of Alzheimer’s or genetic risk factors.
In addition to clinical limits, access remains a key issue for patients in the United States. According to a report by The Town Line Newspaper, getting a diagnosis traditionally takes more than three years after symptoms first appear. While new blood tests offer faster clarity, advocates are calling on Congress to pass the bipartisan Alzheimer’s Screening and Prevention, or ASAP, Act to guarantee Medicare coverage for these novel diagnostic tools.
The Town Line Newspaper noted that long-term care for Alzheimer’s costs between $72,800 and $115,000 per year, with family caregivers contributing over 19 billion hours of unpaid care valued at more than $446 billion. Earlier detection allows families to plan for caregiving costs before irreversible neuron damage occurs, making widespread access and insurance coverage critical next steps for health systems.



